1070 related articles for article (PubMed ID: 21450214)
1. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
2. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
3. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.
Pergola PE; Gartenberg G; Fu M; Sun S; Wolfson M; Bowers P
Clin J Am Soc Nephrol; 2010 Apr; 5(4):598-606. PubMed ID: 20185602
[TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.
Spinowitz B; Germain M; Benz R; Wolfson M; McGowan T; Tang KL; Kamin M;
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1015-21. PubMed ID: 18400964
[TBL] [Abstract][Full Text] [Related]
7. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
[TBL] [Abstract][Full Text] [Related]
8. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
Provenzano R; Singh AK
Endocr Pract; 2007; 13(3):251-9. PubMed ID: 17599856
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.
Pergola PE; Gartenberg G; Fu M; Wolfson M; Rao S; Bowers P
Clin J Am Soc Nephrol; 2009 Nov; 4(11):1731-40. PubMed ID: 19808215
[TBL] [Abstract][Full Text] [Related]
10. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
Kessler M; MartÃnez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
[TBL] [Abstract][Full Text] [Related]
11. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
[TBL] [Abstract][Full Text] [Related]
12. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
13. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease.
Benz R; Schmidt R; Kelly K; Wolfson M
Clin J Am Soc Nephrol; 2007 Mar; 2(2):215-21. PubMed ID: 17699416
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.
Levine AM; Salvato P; Leitz GJ;
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):131-9. PubMed ID: 18284320
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
17. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
18. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
19. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
20. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]